UNSPSC 51273104: Hydroxydione

This classification denotes an anesthetic agent with the molecular formula C25H35O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 53J8I8O5EW, chemically known as 4-[2-[(5R,8R,9S,10S,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2-oxoethoxy]-4-oxobutanoate but generally known as hydroxydione, which bears US NIH Compound Identifier 23689389.

European Medicines Agency schedules Hydroxydione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08078MIG. The term HYDROXYDIONE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 16, No. 3 1962, List 4). As of Q4 2014, HYDROXYDIONE remains the US FDA Preferred Term for this commodity. SMILES: CC12CCC(=O)CC1CCC3C2CCC4(C3CCC4C(=O)COC(=O)CCC(=O)[O-])C.

UNSPSC 51273104 Hydroxydione is a Commodity code that describes pharmaceutical active ingredients and finished drug formulations; state and local governments soliciting under it are actually buying naloxone kits, generic multi-source pharmaceuticals, over-the-counter products, and related drug-administration systems for public health, emergency response, and employee health benefit programs. The issuing bodies are state health and human services agencies, county health departments, and cooperative purchasing alliances that aggregate demand across multiple jurisdictions. Scope includes both direct procurement of finished pharmaceuticals through authorized wholesalers and market-intelligence gathering for prescription-fulfillment programs that bypass traditional pharmacy benefit managers.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida released an IFB (IFB60459723LAS, due July 26, 2023) to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the county community health building, requiring vendors to include all shipping costs and comply with E-Verify and drug-free workplace certification. The Texas Health and Human Services Commission posted an RFI (HHS0017013, April 3, 2026) to gather vendor capabilities for a direct-to-manufacturer prescription program serving self-insured state employee plans outside traditional PBM arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP (S1070000015802, due March 26, 2026) to establish multi-award contracts for generic pharmaceuticals and OTC products distributed through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson) across participating state and local facilities including Oregon; evaluation weighs price competitiveness at 75 percent and administrative compliance at 25 percent, with awarded vendors subject to a 3 percent administrative fee and performance penalties of $200 to $1,500 per violation.